Enobasarm has "limited" effects on other androgen-responsive tissues however not "no" effects on other androgen-responsive tissues. Hmmm... sounds like it will not be any better then Oxandrolone also Oxandrolone helps with anemia where Wikipedia states: With Enbosarm the most common side effects reported among all subjects in the trial were fatigue, anemia, nausea and diarrhea.
Anabolics alone effect the LH secretion and it's not being mention with Enbosarm hmmm... red flag here.
This post seems very wierd for this board. This board is about GTx stock and value. I am puzzled why you would talk about a product that may or may not be better since that is not relevant. Since there are no approved drugs in the indication that GTx is using Enobosarm in, then it does not really matter to the stock value as to whether a drug developed in 1964 might be better. What is relevant is whether Enobosarm meets the endpoints necessary for approval.